Lucia Cinque

WhiteLab Genomics is a TechBio company dedicated to unleashing the full power of genomic medicine with Artificial Intelligence. Founded in 2019 and backed by Y Combinator and the French Tech 2030 program, WhiteLab operates at the intersection of AI, computational biology, and structural biology, with offices in Paris, Boston, and Montréal. WhiteLab’s proprietary AI platform enables the rational design and optimization of delivery systems including viral and non-viral vectors, as well as RNA and DNA payloads. The company supports partners across a wide range of therapeutic areas, including but not limited to oncology, neurology, ophthalmology, auditory disorders, and rare diseases. WhiteLab’s mission is to unleash the potential of genomic medicine through advanced artificial intelligence, empowering scientists to design safer, more effective therapies from discovery through preclinical stages. WhiteLab collaborates with leading companies, including Sanofi, Cytiva and Debiopharm, and benefits from a strong network of top-tier academic partners such as the Brain Institute (ICM), the Vision Institute, the University of Massachusetts, and Genethon.

Woerwag Pharma GmbH & Co. KG is a family-owned and international operating pharmaceutical company headquartered in Boeblingen, Germany, developing and selling biofactor preparations wordwide with 1200 employees in more than 35 countries. The company’s product rage is exclusively available in pharmacies and includes both prescription preparations as well as over the counter (OTC) products and food supplements. Therapeutic areas focus on diabetic comorbidities, diseases of the nervous system, of the musculoskeletal system, as well as on stabilizing the immune system. This year, the company celebrates its 50th anniversary.

WhiteLab Genomics is a TechBio company dedicated to unleashing the full power of genomic medicine with Artificial Intelligence. Founded in 2019 and backed by Y Combinator and the French Tech 2030 program, WhiteLab operates at the intersection of AI, computational biology, and structural biology, with offices in Paris, Boston, and Montréal. WhiteLab’s proprietary AI platform enables the rational design and optimization of delivery systems including viral and non-viral vectors, as well as RNA and DNA payloads. The company supports partners across a wide range of therapeutic areas, including but not limited to oncology, neurology, ophthalmology, auditory disorders, and rare diseases. WhiteLab’s mission is to unleash the potential of genomic medicine through advanced artificial intelligence, empowering scientists to design safer, more effective therapies from discovery through preclinical stages. WhiteLab collaborates with leading companies, including Sanofi, Cytiva and Debiopharm, and benefits from a strong network of top-tier academic partners such as the Brain Institute (ICM), the Vision Institute, the University of Massachusetts, and Genethon.